Rep. David Taylor Sells Off Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Representative David Taylor (R-Ohio) recently sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Vertex Pharmaceuticals stock on January 29th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/29/2026.

Vertex Pharmaceuticals Stock Up 1.1%

NASDAQ:VRTX opened at $470.52 on Thursday. The company has a market cap of $119.38 billion, a P/E ratio of 33.18 and a beta of 0.30. The firm’s 50 day moving average is $456.21 and its two-hundred day moving average is $427.39. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $4.38 EPS. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Access Investment Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the second quarter worth $27,000. Chesapeake Asset Management LLC grew its holdings in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares in the last quarter. Eagle Bay Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth $29,000. Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Colonial Trust Co SC lifted its holdings in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 38 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Leerink Partners boosted their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Royal Bank Of Canada raised Vertex Pharmaceuticals from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $455.00 to $546.00 in a research note on Thursday, January 22nd. Evercore ISI increased their target price on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Stifel Nicolaus cut their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a report on Tuesday, November 4th. Finally, Barclays raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $414.00 to $606.00 in a research report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $522.68.

Insider Activity

In other news, Chairman Jeffrey M. Leiden sold 63,781 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the sale, the chairman directly owned 24,026 shares of the company’s stock, valued at approximately $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total value of $4,394,252.00. Following the sale, the executive vice president owned 37,725 shares of the company’s stock, valued at approximately $17,391,225. This trade represents a 20.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 165,105 shares of company stock worth $73,858,523 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.